Genetron Health Landed on Nasdaq, reaching the largest IPO in the history of global cancer precision medicine

On June 19, 2020 (Beijing, China), Guangdong Medical Valley's star enterprise Genetron Health was officially listed on the NASDAQ exchange in New York with the stock code "GTH". In this IPO, Genetron Health issued a total of 16 million American Depository Shares (ADS) at a public offering price of US$16 per share, and raised a total of approximately US$260 million, achieving the largest cancer precision medicine in the history of the world Listed projects of the company. 

Genetron (Nasdaq: GTH) is a leading cancer precision medicine company in China, focusing on cancer genomics research and applications, and is committed to changing the way of cancer diagnosis and treatment relying on advanced molecular biology and big data analysis capabilities. Genetron Health has built a comprehensive product and service pipeline, covering the entire cancer cycle from early cancer screening to diagnosis and treatment recommendations, to monitoring and prognostic management.